Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02733042
Title A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)
Acronym FUSION NHL 001
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Celgene Corporation
Indications
Therapies
Age Groups: adult
Covered Countries USA | NLD | ITA | GBR | FRA | DEU


No variant requirements are available.